Nested Therapeutics
@nestedtx
Followers
122
Following
25
Media
25
Statuses
40
Nested aims to advance precision oncology medicine by finding new driver mutations hiding in plain sight to reach a broader group of patients.
Cambridge, Massachusetts
Joined March 2022
RT @BiotechTVHQ: AACR24: Having entered the clinic last night, @nestedtx's CEO discusses the preclinical profile of a brain-penetrant, pa….
0
2
0
Our CSO, @ Klaus Hoeflich, recently sat down with @ Sally Church on Nested’s progress. Check out the interview on Biotech Strategy Blog and discover our impressive journey from concept to clinic in just three years. #NST628 #NestedTherapeutics #biotech .
0
0
0
RT @OncWeekly: FDA clears @nestedtx Nested Therapeutics' IND application for NST-628, a promising treatment for solid tumors. #oncology #ca….
0
1
0
RT @CD_AACR: Just published with the #AACR24 New Drugs on the Horizon presentation—.The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is….
0
11
0
RT @ElizSMcKenna: Congratulations to Klaus Hoeflich and co-authors at @nestedtx on this simultaneous #AACR24 publication in @CD_AACR! https….
0
5
0
Yesterday at AACR, we unveiled the preclinical data on our lead program, NST-628, during an oral presentation as part of the “New Drugs on the Horizon” series. For more insights, visit our website and stay tuned for more updates!.
0
0
3
We're proud to announce the FDA clearance of our IND Application for NST-628. Additionally, our CSO, will present pre-clinical data on NST-628 at the “New Drugs on the Horizon” Series at the 2024 AACR Annual Meeting. Stay tuned for more updates!
0
1
5
Today, we announce the appointment of three members to our board of directors. “We look forward to partnering with them as we continue to build our pipeline and advance our first program into the clinic this year.” - Darrin Miles, CEO.
0
0
0
We are thrilled to share we’ve been recognized in BioSpace's prestigious NextGen Bio Class of 2024 of the hottest new life sciences companies. Cheers to an extraordinary journey ahead! #NextGen2024 #Innovation. Learn more here:
0
0
0
RT @NatureBiotech: Our list of the best R&D-intensive startups spun out of universities in 2022 includes companies correcting misfolded pro….
0
10
0
We're excited to be featured in “Precision Oncology News” highlighting our co-founders, innovative platform and growing pipeline. Our lead compound NST-628, is anticipated to enter clinical trials in early 2024. Read more about us & the compelling science here!
0
0
2
Happy #Thanksgiving from all of us at Nested Tx! . As we head into the holiday season, let's take a moment to unwind and reflect on the impactful contributions we make every day. May this time be filled with relaxation, joy, and moments of #gratitude with loved ones!
0
0
0
Exciting news! @NewEnglandVC is set to host its 11th Annual NEVYs, and we've just received a nomination for the Emerging Life Science Company of the Year award! . Curious to find out the results? Join us on December 7th at 🏆 #NEVYs23 #LifeScienceAward
0
0
1
We are #hiring! This position will be responsible for developing and preparing global regulatory strategies for multiple programs. Reach out to learn more about us and our unique platform at careers@nestedtx.com!. #precisiononcology #clinicaldevelopment #biotech
0
0
1
A huge round of applause to our presenters for an exceptional job representing Nested Therapeutics at the AACR-NCI-EORTC Conference in Boston! The team’s passion, expertise and dedication shined through as they showcased our strides made with NST-628. #PrecisionMedicine
0
0
0
Today, at the 2023 AACR-NCI-EORTC Conference, we unveiled the first preclinical data on the mechanism of action, efficacy and brain penetrance of our lead candidate, NST-628, a mechanistically novel non-degrading molecular glue targeting multiple nodes in the RAS/MAPK pathway.
1
0
0
RT @DarArvin: Thanks @NatureBiotech for the great writeup! What an honor to be alongside stellar and dedicated founders, amazing investors….
0
4
0